HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B – Biotechknowledgist

Tuesday, September 8

Previous ArticleA Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world Practice

Next Article Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.

clinicaltrials.gov

Leave A Reply